WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 61 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–96) and Recommended (1–57) International Nonproprietary Names can be found in Cumulative List No. 12, 2007 (available in CD-ROM only).
Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 61 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9); Résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–96) et recommandées (1–57) dans la Liste récapitulative No. 12, 2007 (disponible sur CD-ROM seulement).
Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI) Denominaciones Comunes Internacionales RECOMENDADAS: Lista 61 De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [Act. Of. Mund. Salud, 1955, 60, 3 (Resolución EB15.R7); 1969, 173, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia. Las listas de Denominaciones Comunes Internacionales Propuestas (1–96) y Recomendadas (1–57) se encuentran reunidas en Cumulative List No. 12, 2007 (disponible sólo en CD-ROM). 49
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
Latin, English, French, Spanish: Recommended INN DCI Recommandée DCI Recomendada
Chemical name or description; Molecular formula; Graphic formula Nom chimique ou description; Formule brute; Formule développée Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada
acidum levomefolicum levomefolic acid acide lévoméfolique ácido levomefólico
N-(4-{[(2-amino-5-methyl-4-oxo-3,4,5,6,7,8-hexahydropteridin6-yl)methyl]amino}benzoyl)-L-glutamic acid acide N-[4-({[(6S)-2-amino-5-méthyl-4-oxo-1,4,5,6,7,8hexahydroptéridin-6-yl]methyl}amino)benzoyl]-L-glutamique ácido N-(4-{[(2-amino-5-metil-4-oxo-3,4,5,6,7,8-hexahidropteridin6-il)metil]amino}benzoilo)-L-glutámico C20H25N7O6 O O N H2 N N H CH3 N N H N H H H N H CO2H CO2H
aderbasibum aderbasib aderbasib aderbasib
methyl (6S,7S)-7-(hydroxycarbamoyl)-6-(4-phenylpiperazine1-carbonyl)-5-azaspiro[2.5]octane-5-carboxylate (6S,7S)-7(hydroxycarbamoyl)-6-[(4-phénylpipérazin-1-yl)carbonyl]5-azaspiro[2.5]octane-5-carboxylate de méthyle (6S,7S)-6-(4-fenilpiperazina-1-carbonil)-7-(hidroxicarbamoil)5-azaspiro[2.5]octano-4-carboxilato de metilo C21H28N4O5 H3C O N O O N H H O NH OH N
50
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
adoprazinum adoprazine adoprazine adoprazina
1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophenyl)pyridin3-yl]methyl}piperazine 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-{[5-(4-fluorophényl)pyridin3-yl]méthyl}pipérazine 1-(2,3-dihidro-1,4-benzodioxin-5-il)-4-{[5-(4-fluorofenil)piridin3-il]metil}piperazina C24H24FN3O2 F O O N N N
alipogenum tiparvovecum # alipogene tiparvovec
recombinant adeno-associated virus serotype 1 (AAV1) vector expressing the S447X variant of the human lipoprotein lipase (LPL) gene vecteur adéno-associated virus de type 1 (AAV1) recombinant exprimant le variant S447X du gène humain de la lipoprotéine lipase (demander confirmation de la traduction à MPL et RBD) vector viral adeno-asociado recombinante de tipo 1 (AAV1) que expresa la variante S447X del gen humano de lipoproteina lipasa (LPL)
alipogène tiparvovec
alipogén tiparvovec
apricoxibum apricoxib apricoxib apricoxib
4-[2-(4-ethoxyphenyl)-4-methyl-1H-pyrrol-1-yl]benzenesulfonamide 4-[2-(4-éthoxyphényl)-4-méthyl-1H-pyrrol-1-yl]benzènesulfonamide 4-[2-(4-etoxifenil)-4-metil-1H-pirrol-1-il]bencenosulfonamida C19H20N2O3S H3C O O O S NH2 N
H3C
51
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
bafetinibum bafetinib bafétinib bafetinib
N-{3-[([5,5'-bipyrimidin]-2-yl)amino]-4-methylphenyl}-4-{[(3S)-3(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide N-[3-([5,5'-bipyrimidin]-2-ylamino)-4-méthylphényl]-4-{[(3S)-3(diméthylamino)pyrrolidin-1-yl]méthyl}-3-(trifluorométhyl)benzamide N-{3-[([5,5'-bipirimidin]-2-il)amino]-4-metilfenil}-4-{[(3S)-3(dimetilamino)pirrolidin-1-il]metil}-3-(trifluorometil)benzamida C30H31F3N8O N H3C N CH3 F3C O H N H N N CH3 N
N N
H
bederocinum bederocin bédérocine bederocina
2-{[3-({[4-bromo-5-(1-fluoroethenyl)-3-methylthiophen2-yl]methyl}amino)propyl]amino}quinolin-4(1H)-one 2-{[3-({[4-bromo-5-(1-fluoroéthényl)-3-méthylthiophén2-yl]méthyl}amino)propyl]amino}quinoléin-4(1H)-one 2-{[3-({[4-bromo-5-(1-fluoroetenil)-3-metiltiofen2-il]metil}amino)propil]amino}quinolin-4(1H)-ona C20H21BrFN3OS Br H3C H N H N H N S F CH2
O
befiradolum befiradol béfiradol befiradol
(3-chloro-4-fluorophenyl)[4-fluoro-4-({[(5-methylpyridin2-yl)methyl]amino}methyl)piperidin-1-yl]methanone (3-chloro-4-fluorophényl)[4-fluoro-4-({[(5-méthylpyridin2-yl)méthyl]amino}méthyl)pipéridin-1-yl]méthanone (3-cloro-4-fluorofenil){4-fluoro-4-[({(5-metilpiridin2-il)metil}amino)metil]piperidin-1-il}metanona C20H22ClF2N3O F Cl O N F N H N
CH3
52
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
bevasiranibum bevasiranib
siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production duplex of thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')guanylyl-(3'→5')-guanylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')uridylyl-(3'→5')-guanosine and thymidylyl-(3'→5')-thymidylyl-(3'→5')cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')adenylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')guanylyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')cytidylyl-(3'→5')-adenylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')cytidylyl-(3'→5')-cytidylyl-(3'→5')-adenosine petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de l’endothélium vasculaire (VEGF) duplex de thymidylyl-(3'→5')-thymidylyl-(3'→5')-uridylyl-(3'→5')guanylyl-(3'→5')-guanylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')uridylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-uridylyl-(3'→5')uridylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')guanylyl-(3'→5')-uridylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')uridylyl-(3'→5')-guanosine et thymidylyl-(3'→5')-thymidylyl-(3'→5')cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')adénylyl-(3'→5')-cytidylyl-(3'→5')-cytidylyl-(3'→5')-guanylyl-(3'→5')guanylyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')cytidylyl-(3'→5')-adénylyl-(3'→5')-cytidylyl-(3'→5')-uridylyl-(3'→5')cytidylyl-(3'→5')-cytidylyl-(3'→5')-adénosine ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor vascular de crecimiento endotelial (VEGF) duplex de timidilil-(3'→5')-timidilil-(3'→5')-uridilil-(3'→5')-guanilil(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-uridilil(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-uridilil-(3'→5')citidilil-(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-uridilil(3'→5')-citidilil-(3'→5')-guanilil-(3'→5')-uridilil-(3'→5')-guanosina y timidilil-(3'→5')-timidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')guanilil-(3'→5')-guanilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-uridilil(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenosina C401H502N153O290P40 (3'-5') dT dT U G G (5'-3') A C C
bévasiranib
bevasiranib
. . . A . G . U . G . G . U . U . C . C . G . G . U . C . G . U . G . U C A C C A A G G C C A G
C A C dT dT
catridecacogum # catridecacog catridécacog catridecacog
human Factor XIII [A2] homodimer (allele F13A*1B), recombinant DNA origin chaîne A du facteur XIII de coagulation humain non-activée (allèle F13A*1B), homodimère, origine ADN recombinant cadena A del factor XIII de coagulación humano no activado (alelo F13A*1B), homodímero, origen ADN recombinante
53
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
C3708H5735N1013O1111S28 SETSRTAFGG HLFKERWDTN VEYVIGRYPQ KCIVGKFRMY REEYVLNDIG GRGNPIKVSR EYRSSENPVR DIFLEEDGNV ENSDGMYRCG VVENVDATHI GAKKPLNTEG AYLSANITFY QASLHFFVTA EFTNPLKETL GHRKLIASMS RRAVPPNNSN KVDHHTDKYE ENKGTYIPVP VAVWTPYGVL VIFYGEVNDI VGSAMVNAKD YGQCWVFAGV NSKLTKDSVW PASVQAIKHG GKLIVTKQIG VMKSRSNVDM TGVPKAEFKK RINETRDVLA RNVWVHLDGP SDSLRHVYGE AAEDDLPTVE NNKLIVRRGQ IVSELQSGKW RTSRNPETDT KTRSWSYGQF DEGVLVGSWD FNTFLRCLGI NYHCWNEAWM HVCFQFDAPF GDGMMDITDT DFEVENAVLG ETFDVTLEPL KQKSTVLTIP GVTRPMKKMF LDVQIQRRPS OH H N H CO2H
LQGVVPRGVN SFYVQIDFSR GAKIVMREDR YILFNPWCED EDGILDTCLY NIYAYGVPPS PARIVTNYFS TRPDLPVGFG VFAEVNSDLI YKFQEGQEEE KDFKLSITFR SFKKEAVLIQ EIIIKVRGTQ REIRPNSTVQ M
LQEFLNVTSV PYDPRRDLFR SVRLSIQSSP DAVYLDNEKE VMDRAQMDLS AWTGSVDILL AHDNDANLQM GWQAVDSTPQ YITAKKDGTH RLALETALMY NNSHNRYTIT AGEYMGQLLE VVGSDMTVTV WEEVCRPWVS
50 100 150 200 250 300 350 400 450 500 550 600 650 700 731
Modified residues / Résidus modifiés / Residuos modificados
S 1 N-acetylSer
O H3C
citatuzumabum bogatoxum # citatuzumab bogatox
immunoglobulin Fab fusion protein, anti-[Homo sapiens tumorassociated calcium signal transducer 1 (TACSTD1, gastrointestinal tumor-associated protein 2, GA733-2, epithelial glycoprotein 2, EGP2, epithelial cell adhesion molecule Ep-CAM, KSA, KS1/4 antigen, M4S, tumor antigen 17-1A, CD326)], humanized Fab fused with Bougainvillea spectabilis Willd rRNA N-glycosidase [type I ribosome inactivating protein (RIP), bouganin], VB6-845; gamma1 heavy chain fragment (1-225) [hexahistidyl (1-6) -humanized VH from 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1-hinge fragment EPKSC (123-225)], (225-219')-disulfide with kappa fusion chain (1'-481') [humanized V-KAPPA from clone 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219') -12-mer furin linker (proteolytic cleavage spacer from Pseudomonas exotoxin A) (220'-231') -Bougainvillea spectabilis Willd bouganin fragment (27-276 from precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'481')] immunoglobuline Fab protéine de fusion, anti-[Homo sapiens transducteur 1 du signal calcium associé aux tumeurs (TACSTD1, protéine 2 associée aux tumeurs gastrointestinales, GA733-2, glycoprotéine épithéliale 2, EGP-2, molécule d’adhésion de la cellule épithéliale Ep-CAM, KSA, antigène KS1/4, M4S1, antigène tumoral 17-1A, CD326)], humanisé Fab fusionné avec la N-glycosidase de l’ARNr [protéine de type I inactivant le ribosome (RIP), bouganine] de Bougainvillea spectabilis Willd, VB6-845; fragment de chaîne lourde gamma1 (1-225) [hexahistidyl (1-6) -VH humanisé de 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1fragment de la charnière EPKSC (123-225)], (225-219')-disulfure avec la chaîne kappa de fusion (1'-481') [V-KAPPA humanisé du clone 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'-219') -12-mer furin linker (motif de clivage protéolytique de Pseudomonas exotoxin A) (220'-231') Bougainvillea spectabilis Willd bouganine fragment (27-276 du précurseur, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')]
citatuzumab bogatox
54
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
citatuzumab bogatox
inmunoglobulina Fab proteina de fusión, anti-[Homo sapiens transductor 1 de la señal de calcio asociado a tumores (TACSTD1, proteina 2 asociada a tumores gastrointestinales, GA733-2, glicoproteíne epitelial 2, EGP-2, molécula de adhesión de la célula epitelial Ep-CAM, KSA, antígeno KS1/4, M4S1, antígeno tumoral 171A, CD326)], humanizado Fab fusionado con la N-glicosidasa de ARNr [proteína de tipo I inactivadora del ribosoma (RIP), buganina] de Bougainvillea spectabilis Willd, VB6-845; fragmento de cadena pesada gamma1 (1-225) [hexahistidil (1-6) -VH humanizado de 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGHJ4*01, V124>L) [8.8.9] (7-122) -Homo sapiens IGHG1*01 CH1fragmento de la bisagra EPKSC (123-225)], (225-219')-disulfuro con la cadena kappa de fusión (1'-481') [V-KAPPA humanizado del clon 4D5MOC-B (Homo sapiens FR/Mus musculus CDR, Homo sapiens IGKJ1*01, I126>L) [11.3.9] (1'-112') -Homo sapiens IGKC*01 (113'219') -12-mer ligante de furina (espaciador de ruptura proteolítica de Pseudomonas exotoxin A) (220'-231') – buganina de Bougainvillea spectabilis Willd fragmento (27-276 del precursor, V354'>A, D358'>A, Y364'>N, I383'>A) (232'-481')] C3455H5371N921O1060S18 Heavy chain / Chaîne lourde / Cadena pesada HHHHHHEVQL VQSGPGLVQP GGSVRISCAA LEWMGWINTY TGESTYADSF KGRFTFSLDT YCARFAIKGD YWGQGTLLTV SSASTKGPSV VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ QTYICNVNHK PSNTKVDKKV EPKSC SGYTFTNYGM SASAAYLQIN FPLAPSSKST SSGLYSLSSV NWVKQAPGKG SLRAEDTAVY SGGTAALGCL VTVPSSSLGT 50 100 150 200 225
Light chain-toxin / Chaîne légère-toxine / Cadena ligera-toxina DIQMTQSPSS LSASVGDRVT ITCRSTKSLL HSNGITYLYW LLIYQMSNLA SGVPSRFSSS GSGTDFTLTI SSLQPEDFAT RTFGQGTKVE LKRTVAAPSV FIFPPSDEQL KSGTASVVCL VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD VTHQGLSSPV TKSFNRGECT RHRQPRGWEQ LYNTVSFNLG DLRNELAKGT PVCQLPVTLQ TIADDKRFVL VDITTTSKKT YVVGYQDKWD GKDRAVFLDK VPTVATSKLF PGVTNRVTLT AAKADRKALE LGVNKLEFSI EAIHGKTING QEAAKFFLIV KYIETEVVDR GLYGSFKPNF KVLNLENNWG DISDAIHKSS QLISPSNDPW VVNKVSQISP DMGILKFKSS K
YQQKPGKAPK YYCAQNLEIP LNNFYPREAK YEKHKVYACE EAYEYPTFIQ VKVAIDVTDV FDGSYQKLVN IQMVSEAARF PQCTTINPAL
50' 100' 150' 200' 250' 300' 350' 400' 450' 481'
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 23'-93' 28-102 139'-199' 149-205 219'-225 263'-443'
conatumumabum # conatumumab
immunoglobulin G1, anti-[Homo sapiens tumor necrosis factor receptor superfamily member 10B (TNFRSF10B, death receptor 5, DR5, TNF-related apoptosis-inducing ligand receptor 2, TRAIL-R2, TR-2, CD262)], Homo sapiens monoclonal antibody, XG1-048 v w (or AMG 655, TRAIL-R2mAb); gamma1 heavy chain (1-452) [Homo sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) IGHG1*03 (123-452)], (225-215')-disulfide with kappa light chain (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (231-231'':234-234'')-bisdisulfide dimer
55
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
conatumumab
immunoglobuline G1, anti-[Homo sapiens membre 10B de la superfamille des récepteurs du facteur de nécrose tumorale (TNFRSF10B, death receptor 5, DR5, TRAIL-R2, TR-2, CD262)], Homo sapiens anticorps monoclonal, XG1-048 v w (ou AMG 655, TRAIL-R2mAb); chaîne lourde gamma1 (1-452) [Homo sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') IGKC*01 (109'-215')]; dimère (231-231'':234-234'')-bisdisulfure inmunoglobulina G1, anti-[Homo sapiens miembro 10B de la superfamilia de receptores del factor de necrosis tumoral (TNFRSF10B, receptor mortal 5, DR5, TRAIL-R2, TR-2, CD262)], Homo sapiens anticorps monoclonal, XG1-048 v w (o AMG 655, TRAIL-R2mAb); cadena pesada gamma1 (1-452) [Homo sapiens VH (IGHV4-30-4-(IGHD)-IGHJ6*01) [8.7.14] (1-122) -IGHG1*03 (123452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215') [Homo sapiens V-KAPPA (IGKV3-20-IGKJ1*01) [7.3.9] (1'-108') IGKC*01 (109'-215')]; dímero (231-231'':234-234'')-bisdisulfuro C6466H10006N1730O2024S40 Heavy γ1-chain / Chaîne lourde γ1 / Cadena pesada γ1 QVQLQESGPG LVKPSQTLSL TCTVSGGSIS SGDYFWSWIR GHIHNSGTTY YNPSLKSRVT ISVDTSKKQF SLRLSSVTAA RGGDYYYGMD VWGQGTTVTV SSASTKGPSV FPLAPSSKST VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG PVLDSDGSFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNH GK Light κ-chain / Chaîne légère κ / Cadena ligera κ EIVLTQSPGT LSLSPGERAT LSCRASQGIS RSYLAWYQQK GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QGTKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF VDNALQSGNS QESVTEQDSK DSTYSLSSTL TLSKADYEKH GLSSPVTKSF NRGEC Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-97 22''-97'' 23'-89' 23'''-89''' 135'-195' 135'''-195''' 149-205 149''-205'' 215'-225 215'''-225'' 231-231'' 234-234'' 266-326 266''-326'' 372-430 372''-430''
conatumumab
QLPGKGLEWI DTAVYYCARD SGGTAALGCL VTVPSSSLGT GGPSVFLFPP NAKTKPREEQ ISKAKGQPRE QPENNYKTTP YTQKSLSLSP
50 100 150 200 250 300 350 400 450 452
PGQAPSLLIY QFGSSPWTFG YPREAKVQWK KVYACEVTHQ
50' 100' 150' 200' 215'
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación N= Asn-302 Asn-302''
custirsenum custirsen
2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylP-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxyP-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxyP-thioadenylyl-(3'→5')-2'-deoxy-(3'→5')-2'-deoxy-P-thioguanylyl(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxyP-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyluridine
56
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
custirsen
2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2méthoxyéthyl)-P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylP-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxyP-thioguanylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxyP-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxyP-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxyP-thiocytidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-O-(2méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)P-thioadénylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridine 2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxiP-tioadenilil-(3'→5')-2'-desoxi-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxiP-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiouridll-(3'→5')-2'O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metiluridina C231H312N78O119P20S20 (3' 5')d(P-thio)(rC-rA-rG-rC-A-G-C-A-G-A-G-T-C-T-T-C-A-rU-rC-rA-rU) Modified nucleosides A = 2'-O-(2-methoxyethyl)adenosine C = 2'-O-(2-methoxyethyl)-5-methylcytidine G = 2'-O-(2-methoxyethyl)guanosine U = 2'-O-(2-methoxyethyl)-5-methyluridine
custirsén
danusertibum danusertib danusertib danusertib
N-{5-[(2R)-2-methoxy-2-phenylacetyl]-1,4,5,6-tetrahydropyrrolo[3,4c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide N-{5-[(2R)-2-méthoxy-2-phénylacétyl]-1,4,5,6-tétrahydropyrrolo[3,4c]pyrazol-3-yl}-4-(4-méthylpipérazin-1-yl)benzamide N-{5-[(2R)-2-fenil-2-metoxiacetil]-1,4,5,6-tetrahidropirrolo[3,4c]pirazol-3-il}-4-(4-metilpiperazin-1-il)benzamida C26H30N6O3 O NH N H3 C N N HN N O H OCH3
57
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
darotropii bromidum darotropium bromide bromure de darotropium bromuro de darotropio
(1R,3r,5S)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl8-azabicyclo[3.2.1]octan-8-ium bromide bromure de (1R,3r,5S)-3-(2-cyano-2,2-diphényléthyl)-8,8-diméthyl8-azabicyclo[3.2.1]octan-8-ium bromuro de (1R,3r,5S)-3-(2-ciano-2,2-difeniletil)-8,8-dimetil8-azabiciclo[3.2.1]octan-8-io C24H29BrN2
H H NC H N+ CH3 CH3 Br
demiditrazum demiditraz démiditraz demiditraz
2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole 2-[(1S)-1-(2,3-diméthylphényl)éthyl]-1H-imidazole 2-[(1S)-1-(2,3-dimetilfenil)etil]-1H-imidazol C13H16N2 CH3 H H3C HN CH3 N
denenicokinum denenicokin dénénicokine denenicokina
recombinant L-methionyl(human interleukin-21) (134 amino acids), produced in Escherichia coli L-méthionyl(interleukine-21
humaine), recombinante (134 acides aminés), produite par Escherichia coli humana), recombinante (134 aminoácido), producida por Escherichia coli C676H1087N205O203S8 QGQDRHMIRM QKAQLKSANT KKPPKEFLER RQLIDIVDQL GNNERIINVS FKSLLQKMIH KNYVNDLVPE IKKLKRKPPS QHLSSRTHGS FLPAPEDVET TNAGRRQKHR EDS M NCEWSAFSCF LTCPSCDSYE 50 100 133
L-metionil(interleukina-21
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 42-93 49-96
derquantelum derquantel
(1'R,5a'S,7'R,8a'S,9a'R)-1'-hydroxy-1',4,4,8',8',11'-hexamethyl2',3',8a',9,9',10-hexahydro-4H,1'H,5'H,6'H,8'Hspiro[[1,4]dioxepino[2,3-g]indole-8,7'[5a,9a](epiminomethano)cyclopenta[f]indolizin]-10'-one
58
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
derquantel
(1'R,5'aS,7'R,8'aS,9'aR)-1'-hydroxy-1',4,4,8',8',11'-hexaméthyl2',3',8'a,9,9',10-hexahydro-1'H,4H,5'H,6'H,8'Hspiro[[1,4]dioxépino[2,3-g]indole-8,7'[5a,9a](épiminométhano)cyclopenta[f]indolizin]-10'-one (1'R,5a'S,7'R,8a'S,9a'R)-1'-hidroxi-1',4,4,8',8',11'-hexametil2',3',8a',9,9',10-hexahidro-4H,1'H,5'H,6'H,8'Hespiro[[1,4]dioxepino[2,3-g]indol-8,7'[5a,9a](epiminometano)ciclopenta[f]indolizin]-10'-ona C28H37N3O4 H3C O N N H NH O
derquantel
H3C CH3 CH3 OH
O
CH3 CH3
disitertidum disitertide disitertide disitertida
human Transforming Growth Factor-beta receptor type III-(710-723)peptide récepteur de type III du facteur de croissance transformant-bêta humain-(710-723)-peptide receptor de tipo III del factor de crecimiento transformador-beta humano-(710-723)-péptido C68H109N17O22S2 H Thr Ser Leu Asp Ala Ser Ile Ile Trp Ala Met 10
Met Gln Asn OH 14
drinabantum drinabant drinabant drinabant
N-{1-[bis(4-chlorophenyl)methyl]azetidin-3-yl}N-(3,5-difluorophenyl)methanesulfonamide N-{1-[bis(4-chlorophényl)méthyl]azétidin-3-yl}N-(3,5-difluorophényl)méthanesulfonamide N-{1-[bis(4-clorofenil)metil]azetidin-3-il}N-(3,5-difluorofenil)metanosulfonamida C23H20Cl2F2N2O2S O O S Cl N F N CH3 F
Cl
59
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
dulanerminum dulanermin
human tumor necrosis factor ligand superfamily member 10 (TNFrelated apoptosis-inducing ligand or Apo-2 ligand or CD253 antigen)(114-281)-peptide (C-terminal part of the extracellular domain), noncovalent homotrimer membre 10 de la superfamille de ligand du facteur de nécrose tumorale humain (ligand inducteur d’apoptose apparenté au TNF ou Apo-2 ligand ou antigène CD253)-(114-281)-peptide (extrémité -terminale du domaine extracellulaire), homotrimère nonacovalent miembro 10 de la superfamilia de ligandos del factor de necrosis tumoral humano (ligando inductor de apoptosis relacionada con el TNF o Apo-2 ligand o antígeno CD253)-(114-281)-péptido (extremo C-terminal del dominio extracelular), homotrímero nonacovalente C871H1329N243O260S4
dulanermine
dulanermina
Monomer VRERGPQRVA LSNLHLRNGE TSYPDPILLM HLIDMDHEAS AHITGTRGRS LVIHEKGFYY KSARNSCWSK FFGAFLVG NTLSSPNSKN IYSQTYFRFQ DAEYGLYSIY EKALGRKINS EEIKENTKND QGGIFELKEN WESSRSGHSF KQMVQYIYKY DRIFVSVTNE 50 100 150 168
edoxabanum edoxaban
N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-dimethylcarbamoyl)2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine2-carboxamido)cyclohexyl]oxamide N-(5-chloropyridin-2-yl)-N'-[(1S,2R,4S)-4-(N,N-diméthylcarbamoyl)2-(5-méthyl-4,5,6,7-tétrahydro[1,3]thiazolo[5,4-c]pyridine2-carboxamido)cyclohexyl]oxamide N-(5-cloropiridin-2-il)-N'-[(1S,2R,4S)-4-(N,N-dimetilcarbamoil)2-(5-metil-4,5,6,7-tetrahidro[1,3]tiazolo[5,4-c]piridina2-carboxamido)ciclohexil]oxamida C24H30ClN7O4S O H O N S N H3C H N H H O HN O N H N N CH3 Cl CH3
édoxaban
edoxabán
elagolixum elagolix
4-({(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl}amino)butanoic acid
60
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
élagolix
acide 4-({(1R)-2-[5-(2-fluoro-3-méthoxyphényl)-3-{[2-fluoro6-(trifluorométhyl)phényl]méthyl}-4-méthyl-2,6-dioxo3,6-dihydropyrimidin-1(2H)-yl]-1-phényléthyl}amino)butanoïque ácido 4-({(1R)-2-[5-(2-fluoro-3-metoxifenil)-3-{[2-fluoro6-(trifluorometil)fenil]metil}-4-metil-2,6-dioxo-3,6-dihidropirimidin1(2H)-il)-1-feniletil}amino)butanoico C32H30F5N3O5 O H3CO F H3 C N N H O F H N
elagolix
CO2H
F3C
elesclomolum elesclomol élesclomol elesclomol
N,N'-dimethyl-N,N'-di(benzenecarbonothioyl)propanedihydrazide 1-N',3-N'-diméthyl-1-N',3-N'dibenzènecarbonothioylpropanedihydrazide N,N'-dimetil-N,N'-di(bencenocarbonotioil)propanodihidrazida C19H20N4O2S2 CH3 N S N H O O N H CH3 N S
entinostatum entinostat entinostat entinostat
(pyridin-3-yl)methyl ({4-[(2-aminophenyl)carbamoyl]phenyl} methyl)carbamate ({4-[(2-aminophényl)carbamoyl]phényl}méthyl)carbamate de pyridin3-ylméthyle ({4-[(2-aminofenil)carbamoil]fenil}metil)carbamato de (piridin3-il)metilo C21H20N4O3 O N H H N O
NH2
O
N
61
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
eprotiromum eprotirome éprotirome eprotiromo
3-({3,5-dibromo-4-[4-hydroxy-3-(propan-2-yl)phenoxy]phenyl}amino)3-oxopropanoic acid acide 3-({3,5-dibromo-4-[4-hydroxy3-(1-méthyléthyl)phénoxy]phényl}amino)-3-oxopropanoïque ácido 3-({3,5-dibromo-4-[4-hidroxi-3-(propan-2-il)fenoxi]fenil}amino)3-oxopropanoico C18H17Br2NO5 HO H3 C CH3 Br O Br H N O
CO2H
esreboxetinum esreboxetine esréboxétine esreboxetina
(2S)-2-[(2-ethoxyphenoxy)(phenyl)methyl]morpholine (+)-(2S)-2-[(S)-(2-éthoxyphénoxy)phénylméthyl]morpholine (2S)-2-[(2-etoxifenoxi)(fenil)metil]morfolina C19H23NO3
H O H3C O O
H NH
etaracizumabum # etaracizumab
immunoglobulin G1, anti-[Homo sapiens alphaVbeta3 integrin (CD51/CD61, CD51/GPIIIa, CD51/platelet membrane glycoprotein IIIa, vitronectin receptor)], humanized monoclonal antibody, MEDI522 (or hLM609); gamma1 heavy chain (1-447) [humanized VH (Homo sapiens FR/Mus musculus CDR from clone LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfide with kappa light chain (1'214') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR from clone LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; (226-226”:230-230”)-bisdisulfide dimer immunoglobuline G1, anti-[Homo sapiens alphaVbeta3 intégrine (CD51/CD61, CD51/GPIIIa, CD51/glycoprotéine membranaire IIIa des plaquettes, récepteur de la vitronectine)], anticorps monoclonal humanisé, MEDI-522 (ou hLM609); chaîne lourde gamma1 (1-447) [VH humanisé (Homo sapiens FR/Mus musculus CDR du clone LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) -Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR du clone LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'107') -Homo sapiens IGKC*01 (108'-214')]; dimère (226-226”:230230”)-bisdisulfure
étaracizumab
62
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
etaracizumab
inmunoglobulina G1, anti-[Homo sapiens alfaVbeta3 integrina (CD51/CD61, CD51/GPIIIa, CD51/glicoproteina IIIa de membrana de plaquetas, receptor de la vitronectina)], anticuerpo monoclonal humanizado, MEDI-522 (o hLM609); cadena pesada gamma1 (1447) [VH humanizado (Homo sapiens FR/Mus musculus CDR del clon LM609-Homo sapiens IGHJ5*01, L123>T) [8.8.10] (1-117) Homo sapiens IGHG1*03 (118-447)], (220-214’)-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (Homo sapiens FR/Mus musculus CDR del clon LM609-Homo sapiens IGKJ4*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (226226”:230-230”)-bisdisulfuro C6392H9908N1732O1996S42 γ−Heavy chain/ Chaîne γ lourde / Cadena γ pesada QVQLVESGGG VSSGGGSTYY HGSFASWGQG PEPVTVSWNS NVNHKPSNTK LMISRTPEVT RVVSVLTVLH LPPSREEMTK DGSFFLYSKL VVQPGRSLRL LDTVQGRFTI TTVTVSSAST GALTSGVHTF VDKRVEPKSC CVVVDVSHED QDWLNGKEYK NQVSLTCLVK TVDKSRWQQG SCAASGFTFS SRDNSKNTLY KGPSVFPLAP PAVLQSSGLY DKTHTCPPCP PEVKFNWYVD CKVSNKALPA GFYPSDIAVE NVFSCSVMHE SYDMSWVRQA LQMNSLRAED SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS PGKGLEWVAK TAVYYCARHL ALGCLVKDYF SSLGTQTYIC FLFPPKPKDT PREEQYNSTY GQPREPQVYT YKTTPPVLDS LSLSPGK 50 100 150 200 250 300 350 400 447
κ−Light chain / Chaîne κ légère/ Cadena κ ligera EIVLTQSPAT RSQSISGIPA GTKVEIKRTV DNALQSGNSQ LSSPVTKSFN LSLSPGERAT RFSGSGSGTD AAPSVFIFPP ESVTEQDSKD RGEC LSCQASQSIS FTLTISSLEP SDEQLKSGTA STYSLSSTLT NFLHWYQQRP EDFAVYYCQQ SVVCLLNNFY LSKADYEKHK GQAPRLLIRY SGSWPLTFGG PREAKVQWKV VYACEVTHQG 214' 50' 100' 150' 200'
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 22-96 22''-96'' 23'-88' 23'''-88''' 134'-194' 134'''-194''' 144-200 144''-200'' 261''-321'' 367-425 367''-425''
214'-220 214'''-220'' 226-226'' 229-229'' 261-321
foravirumabum # foravirumab
immunoglobulin G1-kappa, anti-[rabies virus glycoprotein], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-448) [Homo sapiens VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228228'':231-231'')-bisdisulfide dimer immunoglobuline G1-kappa, anti-[glycoprotéine du virus de la rage], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-448) [Homo sapiens VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228228'':231-231'')-bisdisulfure
foravirumab
63
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
foravirumab
inmunoglobulina G1-kappa, anti-[glicoproteína del virus de la rabia], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-448) [Homo sapiens VH (IGHV3-33*03 (95.90%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -IGHG1*03, CH3 K130>del (120-448)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1-17*01 (95.80%) IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228228'':231-231'')-bisdisulfuro C6400H9914N1718O1998S44 Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG AVQPGRSLRL SCAASGFTFS ILYDGSDKFY ADSVKGRFTI SRDNSKNTLY VAGTHFDYWG QGTLVTVSSA STKGPSVFPL YFPEPVTVSW NSGALTSGVH TFPAVLQSSG ICNVNHKPSN TKVDKRVEPK SCDKTHTCPP DTLMISRTPE VTCVVVDVSH EDPEVKFNWY TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL YTLPPSREEM TKNQVSLTCL VKGFYPSDIA DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM Light chain / Chaîne légère / Cadena ligera DIQMTQSPSS LSASVGDRVT ITCRASQGIR ASSLQSGVPS RFSGSGSGTD FTLTISSLQP GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSSPVTKSFN RGEC SYGMHWVRQA LQMNSLRAED APSSKSTSGG LYSLSSVVTV CPAPELLGGP VDGVEVHNAK PAPIEKTISK VEWESNGQPE HEALHNHYTQ NDLGWYQQKP EDFATYYCQQ SVVCLLNNFY LSKADYEKHK PGKGLEWVAV TAVYYCAKVA TAALGCLVKD PSSSLGTQTY SVFLFPPKPK TKPREEQYNS AKGQPREPQV NNYKTTPPVL KSLSLSPG 50 100 150 200 250 300 350 400 448
GKAPKLLIYA 50 LNSYPPTFGG 100 PREAKVQWKV 150 VYACEVTHQG 200 214
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 263-323 369-427 22''-96'' 146''-202'' 263''-323'' 369''-427'' Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 222-214' 222''-214''' Inter-H-H 228-228'' 231-231'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 299, 299''
ibipinabantum ibipinabant
(E,4S)-N′-(4-chlorobenzenesulfonyl)-3-(4-chlorophenyl)-N-methyl4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide (E,4S)-N′-(4-chlorobenzènesulfonyl)-3-(4-chlorophényl)-N-méthyl4-phényl-4,5-dihydro-1H-pyrazole-1-carboximidamide (E,4S)-N′-(4-clorobencenosulfonil)-3-(4-clorofenil)-4-fenil-N-metil4,5-dihidro-1H-pirazol-1-carboximidamida C23H20Cl2N4O2S H3C NH O O S N N Cl
ibipinabant
ibipinabant
H
N
Cl
64
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
intiquinatinum intiquinatine intiquinatine intiquinatina
(2R)-2-{4-[(7-bromoquinolin-2-yl)oxy]phenoxy}propanoic acid acide (2R)-2-{4-[(7-bromoquinoléin-2-yl)oxy]phénoxy}propanoïque ácido (2R)-2-{4-[(7-bromoquinolin-2-il)oxi]fenoxi}propanoico C18H14BrNO4 Br N O H O CH3 CO2H
lancovutidum lancovutide
(C R)-C -hydroxy[2-L-lysine,10-L-phenylalanine, 12-L-phenylalanine-,13-L-valine]lantibiotic ancovenin (Streptomyces sp) (C R)-C -hydroxy[2-L-lysine,10-L-phénylalanine, 12-L-phénylalanine-,13-L-valine]ancovénine antibiotique (Streptomyces sp) C R)-C -hidroxi[2-L-lisina,10-L-fenilalanina,12-L-fenilalanina-, 13-L-valina]ancovenina antibiótico (Streptomyces sp) C89H125N23O25S3 CH3 S H H2N O H Lys Gln N H H N H H N O H HN O S Phe Gly Pro Phe N H S CH3 H Phe Val N H HO2C H H N H OH H Gly Asn N H H H N O CO2H H
3,15
3,15
lancovutide
3,15
3,15
lancovutida
3,15
3,15
O
O
O
O
larazotidum larazotide larazotide larazotida
glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine glicilglicil-L-valil-L-leucil-L-valil-L-glutaminil-L-prolilglicina C32H55N9O10 H Gly Gly Val Leu Val Gln Pro Gly OH
lensiprazinum lensiprazine lensiprazine lensiprazina
(2R)-8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperidin-1-yl}-2-methyl2H-1,4-benzooxazin-3(4H)-one (-)-(2R)-8-{4-[3-(5-fluoro-1H-indol-3-yl)propyl]pipérazin-1-yl}2-méthyl-2H-1,4-benzoxazin-3(4H)-one (2R)-8-{4-[3-(5-fluoro-1H-indol-3-il)propil]piperidin-1-il}-2-metil2H-1,4-benzooxazin-3(4H)-ona
65
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
C24H27FN4O2 F
HN O H O CH3
N N NH
levomilnacipranum levomilnacipran lévomilnacipran levomilnaciprán
(1S,2R)-2-(aminomethyl)-N,N-diethyl1-phenylcyclopropanecarboxamide (-)-(1S,2R)-2-(aminométhyl)-N,N-diéthyl1-phénylcyclopropanecarboxamide (-)-(1S,2R)-2-(aminometil)-N,N-dietil-1-fenilciclopropanocarboxamida C15H22N2O CH3 O N H CH3 NH2
linagliptinum linagliptin linagliptine linagliptina
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione 8-[(3R)-3-aminopipéridin-1-yl]-7-(but-2-yn-1-yl)-3-méthyl1-[(4-méthylquinazolin-2-yl)méthyl]-3,7-dihydro-1H-purine-2,6-dione 8-[(3R)-3-aminopiperidin-1-il]-7-(but-2-in-1-il)-3-metil1-[(4-metilquinazolin-2-il)metil]-3,7-dihidro-1H-purina-2,6-diona C25H28N8O2 CH3 O N N CH3 O N N CH3 N N N H NH2
lixisenatidum lixisenatide lixisénatide lixisenatida
des-38-proline-exendine-4 (Heloderma suspectum)-(1-39)peptidylpenta-L-lysyl-L-lysinamide dés-38-proline-exendine-4 (Heloderma suspectum)-(1-39)peptidylpenta-L-lysyl-L-lysinamide des-38-prolina-exendina-4 (Heloderma suspectum)-(1-39)peptidilpenta-L-lisil-L-lisinamida
66
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
C215H347N61O65S H His Gly Glu Gly Thr Phe Thr Ser Glu Glu Glu Asp Leu Ser Lys Gln Met 10
Ala Val Arg Leu Phe Ile Glu Trp Leu Lys 20
Asn
Gly Gly Pro Ser Ser 30
Gly
Ala Pro Pro Ser Lys Lys Lys Lys 40
Lys Lys NH2 44
macitentanum macitentan macitentan macitentán
N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]ethoxy}pyrimidin4-yl]-N'-propylsulfuric diamide N-[5-(4-bromophényl)-6-{2-[(5-bromopyrimidin2-yl)oxy]éthoxy}pyrimidin-4-yl]-N'-propyldiamide sulfurique N-[5-(4-bromofenil)-6-{2-[(5-bromopirimidin-2-il)oxi]etoxi}pirimidin4-il]-N'-propildiamida sulfúrica C19H20Br2N6O4S O O S N NH H N N O O N N Br
H3C
Br
melogliptinum melogliptin mélogliptine melogliptina
(2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol1-yl)methyl]cyclopentyl}amino)acetyl]pyrrolidine-2-carbonitrile (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol1-yl)méthyl]cyclopentyl}amino)acétyl]pyrrolidine-2-carbonitrile (2S,4S)-4-fluoro-1-[2-({(1R,3S)-3-[(1H-1,2,4-triazol1-il)metil]ciclopentil}amino)acetil]pirrolidina-2-carbonitrilo C15H21FN6O H N H H O N F H CN
N
N N
H
67
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
mimopezilum mimopezil
(5R,9R)-5-{[(5-chloro-2-hydroxy3-methoxyphenyl)methylidene]amino}-11-[(E)-ethylidene]-7-methyl5,6,9,10-tetrahydro-5,9-methanocycloocta[b]pyridin-2(1H)-one (5R,9R)-5-{[(5-chloro-2-hydroxy3-méthoxyphényl)méthylidène]amino}-11-[(E)-ethylidène]-7-méthyl5,6,9,10-tétrahydro-5,9-méthanocycloocta[b]pyridin-2(1H)-one (5R,9R)-5-{[(5-cloro-2-hidroxi-3-metoxifenil)metilideno]amino}11-[(E)-etilideno]-7-metil-5,6,9,10-tetrahidro5,9-metanocicloocta[b]piridin-2(1H)-ona C23H23ClN2O3 H H N O
mimopézil
mimopezilo
H3C H3C N OH OCH3 Cl
mipomersenum mipomersen
antisense oligonucleotide inhibitor of apolipoprotein B (APOB) expression 2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-Pthiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5methyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-O(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O(2-methoxyethyl)-5-methylcytidine oligonucléotide antisens, inhibiteur de l’expression de l’apolipoprotéine B (APOB) 2'-O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-Pthiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')Pthiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-5méthyl-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-Pthiothymidylyl-(3'→5')-2'-désoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'O-(2-méthoxyéthyl)-P-thioguanylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadénylyl(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O(2-méthoxyéthyl)-5-méthylcytidine
mipomersen
68
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
mipomersén
oligonucleótido antisentido inhibidor de la expresión de la apolipoproteina B (APOB) 2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-Ptiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O(2-metoxietil)-5-metil-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-Ptiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-Ptioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi5-metil-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil(3'→5')-2'-O-(2-metoxietil)-5-metil-P-tiocitidilil-(3'→5')-2'-O-(2metoxietil)-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-5-metil-Ptiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metilcitidina C230H324N67O122P19S19 (3'-5')(P-thio)(G-C-C-U-C-dA-dG-dT-dC-dT-dG-dC-dT-dT-dC-G-C-A-C-C) Modified nucleosides / Nucléosides modifiés / Nucleósidos modificados
A N OH O N
N NH2 N OCH3
C : R = O-CH2-CH2-OCH3 dC : R = H OH O O N N NH2 CH3
HO
O H2N NH N O N OCH3 HO R H N N
G
U OH O
OH O N
O
O CH3 OCH3
HO
O
HO
O
niraxostatum niraxostat niraxostat niraxostat
1-[3-cyano-4-(2,2-dimethylpropoxy)phenyl]-1H-pyrazole-4-carboxylic acid acide 1-[3-cyano-4-(2,2-diméthylpropoxy)phényl]-1H-pyrazole4-carboxylique ácido 1-[3-ciano-4-(2,2-dimetilpropoxi)fenil]-1H-pirazol-4-carboxílico C16H17N3O3 N N H3C H3 C CH3 O CN CO2H
69
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
olesoximum olesoxime olésoxime olesoxima
(EZ)-N-(cholest-4-en-3-ylidene)hydroxylamine (EZ)-N-(cholest-4-én-3-ylidène)hydroxylamine (EZ)-N-(colest-4-en-3-ilideno)hidroxilamina C27H45NO H3C CH3 CH3 H HO N H H H H H3C CH3
ombrabulinum ombrabulin ombrabuline ombrabulina
(2S)-2-amino-3-hydroxy-N-{2-methoxy-5-[(1Z)-2-(3,4,5trimethoxyphenyl)ethenyl]phenyl}propanamide (2S)-2-amino-3-hydroxy-N-{2-méthoxy-5-[(1Z)-2-(3,4,5triméthoxyphényl)éthényl]phényl]propanamide (2S)-2-amino-3-hidroxi-N-{2-metoxi-5-[(1Z)-2-(3,4,5trimetoxifenil)etenil]fenil}propanamida C21H26N2O6 H3CO H3CO OCH3 OCH3 N H O OH H NH2
otenabantum otenabant oténabant otenabant
1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]4-(ethylamino)piperidine-4-carboxamide 1-[8-(2-chlorophényl)-9-(4-chlorophényl)-9H-purin-6-yl]4-(éthylamino)pipéridine-4-carboxamide 1-[8-(2-clorofenil)-9-(4-clorofenil)-9H-purin-6-il]4-(etilamino)piperidina-4-carboxamida C25H25Cl2N7O N Cl N N NH NH2 Cl CH3 N O N
70
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
palifosfamidum palifosfamide palifosfamide palifosfamida
N,N'-bis(2-chloroethyl)phosphorodiamidic acid acide N,N'-bis(2-chloroéthyl)phosphorodiamidique ácido N,N'-bis(2-cloroetil)fosforodiamídico C4H11Cl2N2O2P Cl O HO HN P HN Cl
palovarotenum palovarotene palovarotène palovaroteno
4-[(1E)-2-{5,5,8,8-tetramethyl-3-[(1H-pyrazol-1-yl)methyl]5,6,7,8-tetrahydronaphthalen-2-yl}ethenyl]benzoic acid acide 4-{(1E)-2-[5,5,8,8-tétraméthyl-3-(1H-pyrazol-1-ylméthyl)5,6,7,8-tétrahydronaphtalén-2-yl]éthényl}benzoïque ácido 4-[(1E)-2-{5,5,8,8-tetrametil-3-[(1H-pirazol-1-il)metil]5,6,7,8-tetrahidronaftalen-2-il}etenil]benzoico C27H30N2O2 H3C CH3 CO2H
H3C CH3
N
N
radezolidum radezolid
N-{[(5S)-3-(2-fluoro-4'-{[([1H-1,2,3-triazol4-yl]methyl)amino]methyl}[1,1'-biphenyl]-4-yl)-2-oxo-1,3-oxazolidin5-yl]methyl}acetamide N-{[(5S)-3-(2-fluoro-4'-{[(1H-1,2,3-triazol4-ylméthyl)amino]méthyl}biphényl-4-yl)-2-oxo-1,3-oxazolidin5-yl]méthyl}acétamide N-{[(5S)-3-(2-fluoro-4'-{[([1H-1,2,3-triazol-4-il]metil)amino]metil}[1,1'bifenil]-4-il)-2-oxo-1,3-oxazolidin-5-il]metil}acetamida C22H23FN6O3 H H N O F H N O N H N N N O
radézolid
radezolid
H3 C
71
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
rafivirumabum # rafivirumab
immunoglobulin G1-lambda, anti-[rabies virus glycoprotein], Homo sapiens monoclonal antibody; gamma1 heavy chain (1-456) [Homo sapiens VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfide with lambda light chain (1'-218') [Homo sapiens V-LAMBDA (IGLV211*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; (236-236'':239-239'')-bisdisulfide dimer immunoglobuline G1-lambda, anti-[glycoprotéine du virus de la rage], Homo sapiens anticorps monoclonal; chaîne lourde gamma1 (1-456) [Homo sapiens VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfure avec la chaîne légère lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dimère (236236'':239-239'')-bisdisulfure inmunoglobulina G1-lambda, anti-[glicoproteína del virus de la rabia], Homo sapiens anticuerpo monoclonal; cadena pesada gamma1 (1-456) [Homo sapiens VH (IGHV1-69*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.20] (1-127) -IGHG1*03, CH3 K130>del (128-456)], (230-217')-disulfuro con la cadena ligera lambda (1'-218') [Homo sapiens V-LAMBDA (IGLV2-11*01 (94.90%) -IGLJ2*01) [9.3.12] (1'-112') -IGLC2*01 (113'-218')]; dímero (236236'':239-239'')-bisdisulfuro C6462H9954N1718O2036S46 Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VKKPGSSVKV SCKASGGTFN IIPIFGTANY AQRFQGRLTI TADESTSTAY LDNSGTYYYF SGWFDPWGQG TLVTVSSAST ALGCLVKDYF PEPVTVSWNS GALTSGVHTF SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC FLFPPKPKDT LMISRTPEVT CVVVDVSHED PREEQYNSTY RVVSVLTVLH QDWLNGKEYK GQPREPQVYT LPPSREEMTK NQVSLTCLVK YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG LSLSPG Light chain / Chaîne légère / Cadena ligera QSALTQPRSV SGSPGQSVTI SCTGTSSDIG YDATKRPSGV PDRFSGSKSG NTASLTISGL VVFGGGTKLT VLGQPKAAPS VTLFPPSSEE TVAWKADSSP VKAGVETTTP SKQSNNKYAA VTHEGSTVEK TVAPTECS RYTVNWVRQA MELSSLRSDD KGPSVFPLAP PAVLQSSGLY DKTHTCPPCP PEVKFNWYVD CKVSNKALPA GFYPSDIAVE NVFSCSVMHE PGQGLEWMGG TAVYFCAREN SSKSTSGGTA SLSSVVTVPS APELLGGPSV GVEVHNAKTK PIEKTISKAK WESNGQPENN ALHNHYTQKS 50 100 150 200 250 300 350 400 450 456
rafivirumab
rafivirumab
GYNFVSWYQQ QAEDEADYYC LQANKATLVC SSYLSLTPEQ
HPGKAPKLMI 50 CSYAGDYTPG 100 LISDFYPGAV 150 WKSHRSYSCQ 200 218
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 154-210 277-331 377-435 22''-96'' 154''-210'' 277''-331'' 377''-435'' Intra-L 22'-90' 140'-199' 22'''-90''' 140'''-199''' Inter-H-L 230-217' 230''-217''' Inter-H-H 236-236'' 239-239'' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación 307, 307''
72
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
retaspimycinum retaspimycin
(4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22-trihydroxy8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-[(prop-2-en1-yl)amino]-2-azabicyclo[16.3.1]docasa-1(21)4,6,10,18(22),19hexaen-9-yl carbamate carbamate de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22trihydroxy-8,14-diméthoxy-4,10,12,16-tétraméthyl-3-oxo-19-(prop2-énylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19hexén-9-yle carbamato de (4E,6Z,8S,9S,10E,12S,13R,14S,16R)-13,20,22trihidroxi-4,10,12,16-tetrametil-8,14-dimetoxi-3-oxo-19-[(prop-2-en1-il)amino]-2-azabiciclo[16.3.1]docasa-1(21)4,6,10,18(22),19hexaen-9-ilo C31H45N3O8 CH3 O HO H2 C N H H NH OH H H3CO H 3C H OH O H O NH2
rétaspimycine
retaspimicina
H H CH3 OCH3 CH3
saracatinibum saracatinib saracatinib saracatinib
N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin1-yl)ethoxy]-5-(oxan-4-yl)oxy]quinazolin-4-amine N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-méthylpipérazin1-yl)éthoxy]-5-[(oxan-4-yl)oxy]quinazolin-4-amine N-(5-cloro-1,3-benzodioxol-4-il)-7-[2-(4-metilpiperazin-1-il)etoxi]5-[(oxan-4-il)oxi]quinazolin-4-amina C27H32ClN5O5 N H 3C N O O O O HN O N N Cl
semagacestatum semagacestat
(2S)-2-hydroxy-3-methyl-N-[(2S)-1-{[(1S)-3-methyl-2-oxo2,3,4,5-tetrahydro-1H-3-benzazepin-1-yl]amino}-1-oxopropan2-yl]butanamide (2S)-2-hydroxy-3-méthyl-N-[(2S)-1-{[(1S)-3-méthyl-2-oxo2,3,4,5-tétrahydro-1H-3-benzazépin-1-yl]amino}-1-oxopropan2-yl]butanamide
sémagacestat
73
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
semagacestat
(2S)-2-hidroxi-3-metil-N-[(2S)-1-{[(1S)-3-metil-2-oxo2,3,4,5-tetrahidro-1H-3-benzazepin-1-il]amino}-1-oxopropan2-il]butanamida C19H27N3O4 CH3 H 3C H OH O H CH3 N H H H N O N CH3
O
semuloparinum natricum semuloparin sodium
sodium salt of a low molecular mass heparin that is obtained by phosphazene promoted depolymerization of heparin from porcine intestinal mucosa; the majority of the components have a 4-deoxy2-O-sulfo-α-L-threo-hex-4-enopyranosuronic acid structure at the non-reducing end and a 2-deoxy-6-O-sulfo-2-(sulfoamino)D-glucopyranose structure at the reducing end of their chain; the molecular mass is defined by a repartition, no more than 40% is inferior to 1600 and no more than 11% is superior to 4500 Daltons, and by a mass-average value comprised between 2000 and 3000 Daltons; the degree of sulfatation is about 2.0 per disaccharidic unit sel de sodium d'héparine de basse masse moléculaire obtenue par dépolymérisation à l'aide de phosphazène d'héparine de muqueuse intestinale de porc. La majorité des composants présente une structure acide 4-déoxy-2-O-sulfo-α-L-thréo-hex4-énopyranosuronique à l'extrémité non réductrice et une structure 2-déoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité réductrice de leur chaîne ; la masse moléculaire relative du produit est définie par une répartition, au plus 40% inférieur à 1600 et au plus 11% supérieur à 4500, et une moyenne comprise entre 2000 et 3000 ; le degré de sulfatation est voisin de 2 par unité disaccharide sal sódica de la heparina de baja masa molecular obtenida de heparina de mucosa intestinal de cerdo por despolimerización mediante un proceso controlado en el que se utiliza fosfazeno. La mayoría de los componentes presentan la estructura ácido 4-desoxi-2-O-sulfo-α-L-treo-hex-4-enopiranosurónico en el extremo no reductor y la estructura 2-desoxi-6-O-sulfo-2-(sulfoamino)D-glucopiranosa en el extremo reductor de su cadena ; la masa molecular relativa del producto se define por una distribución, en la que, como máximo, un 40% es inferior a 1600 y, como máximo, un 11% es superior a 4500, y la media está comprendida entre 2000 y 3000 ; el grado de sulfatación es aproximadamente 2 por unidad de disacárido
sémuloparine sodique
semuloparina sódica
sivifenum sivifene sivifène sivifeno
4,4'-{[2-(2,4-dinitrophenyl)hydrazinylidene]methylene}diphenol 4,4'-{[(2,4-dinitrophényl)diazanylidène]méthylène}diphénol 4,4'-{[2-(2,4-dinitrofenil)hidrazinilideno]metileno}difenol
74
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
C19H14N4O6 HO O2N N N H NO2
OH
talarozolum talarozole talarozole talarozol
N-{4-[2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl}-1,3-benzothiazol2-amine N-{4-[(1R)-2-ethyl-1-(1H-1,2,4-triazol-1-yl)butyl]phenyl}benzothiazol2-amine N-{4-[2-etil-1-(1H-1,2,4-triazol-1-il)butil]fenil}-1,3-benzotiazol-2-amina C21H23N5S H3 C H3C N N N H H N S N
talmapimodum talmapimod
2-[6-chloro-5-({(2R,5S)-4-[(4-fluorophenyl)methyl]2,5-dimethylpiperazin-1-yl}carbonyl)-1-methyl-1H-indol-3-yl]N,N-dimethyl-2-oxoacetamide 2-[6-chloro-5-({(2R,5S)-4-[(4-fluorophényl)méthyl]2,5-diméthylpipérazin-1-yl}carbonyl)-1-méthyl-1H-indole-3-yl]N,N-diméthyl-2-oxoacétamide 2-[6-cloro-5-({(2R,5S)-4-[(4-fluorofenil)metil]-2,5-dimetilpiperazin1-il}carbonil)-1-metil-1H-indol-3-il]-N,N-dimetil-2-oxoacetamida C27H30ClFN4O3 H CH3 Cl N F N H3C H O O H3 C CH3 N O N CH3
talmapimod
talmapimod
75
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
tanezumabum* tanezumab
immunoglobulin G2, anti-[Homo sapiens nerve growth factor beta (NGFB)], humanized monoclonal antibody, RN624; gamma2 heavy chain (1-447) [humanized VH (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') Homo sapiens IGKC*01 (108'-214')]; (223-223'':224-224'':227227'':230-230'')-tetradisulfide dimer analgesic immunoglobuline G2, anti-[Homo sapiens facteur de croissance beta des nerfs (NGFB)], anticorps monoclonal humanisé, RN624; chaîne lourde gamma2 (1-447) [VH humanisé (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) -Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135-214')disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dimère (223223'':224-224'':227-227'':230-230'')-tetradisulfure analgésique inmunoglobulina G2, anti-[Homo sapiens factor beta de crecimiento de los nervios (NGFB)], anticuerpo monoclonal humanizado, RN624; cadena pesada gamma2 (1-447) [VH humanizada (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGHJ4*01) [8.7.15] (1-121) Homo sapiens IGHG2*01, CH2 A115>S, P116>S (122-447)], (135214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizada (Homo sapiens FR/Mus musculus CDR-Homo sapiens IGKJ2*01) [6.3.9] (1'-107') -Homo sapiens IGKC*01 (108'-214')]; dímero (223-223'':224-224'':227-227'':230-230'')-tetradisulfuro analgésico C6464H9942N1706O2026S46
tanézumab
tanezumab
tasimelteonum tasimelteon tasimeltéon tasimelteón
N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran4-yl)cyclopropyl]methyl}propanamide N-{[(1R,2R)-2-(2,3-dihydro-1-benzofuran4-yl)cyclopropyl]méthyl}propanamide N-{[(1R,2R)-2-(2,3-dihidro-1-benzofuran4-il)ciclopropil]metil}propanamida C15H19NO2 O O N H H CH3
H
76
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
tasisulamum tasisulam tasisulam tasisulam
N-(5-bromothiophene-2-sulfonyl)-2,4-dichlorobenzamide N-[(5-bromothiophén-2-yl)sulfonyl]-2,4-dichlorobenzamide N-(5-bromotiofeno-2-sulfonil)-2,4-diclorobenzamida C11H6BrCl2NO3S2 O O O S N H Cl
Br
S
Cl
taspoglutidum taspoglutide
[8-(2-amino-2-methylpropanoic acid),35-(2-amino-2-methylpropanoic acid)]human glucagon-like peptide 1 (GLP-1)-(7-36)-peptidamide L-histidyl-2-methyl-L-alanyl-L-glutamylglycyl-L-threonylL-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L-valyl-L-seryl-L-serylL-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysylL-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucylL-valyl-L-lysyl-2-methyl-L-alanyl-L-arginamide [8-(acide 2-amino-2-méthylpropanoïque),35-(acide 2-amino2-méthylpropanoïque)]peptide 1 apparenté au glucagon humain (GLP-1)-(7-36)-peptidamide L-histidyl-2-méthyl-L-alanyl-L-glutamylglycyl-L-thréonylL-phénylalanyl-L-thréonyl-L-séryl-L-aspartyl-L-valyl-L-séryl-L-sérylL-tyrosyl-L-leucyl-L-glutamylglycyl-L-glutaminyl-L-alanyl-L-lysylL-glutamyl-L-phénylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucylL-valyl-L-lysyl-2-méthyl-L-alanyl-L-arginamide [8-(ácido 2-amino-2-metilpropanoico),35-(ácido 2-amino2-metilpropanoico)]péptido 1 relacionado con el glucagón humano(7-36)-peptidamida L-histidil-2-metil-L-alanil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonilL-seril-L-aspartil-L-valil-L-seril-L-seril-L-tirosil-L-leucil-L-glutamilglicilL-glutaminil-L-alanil-L-lisil-L-glutamil-L-fenilalanil-L-isoleucil-L-alaniltriptofil-L-leucil-L-valil-L-lisil-2-metil-L-alanil-L-arginamida C152H232N40O45 H His 7
taspoglutide
taspoglutida
Aib Glu Leu 20
Gly Thr 10
Phe Thr Ala Ala
Ser Lys
Asp Glu
Val Phe
Ser Ile
Ser Ala 30
Tyr Trp
Glu Val
Gly Lys
Gln Aib
Leu
Arg NH2 H3C CH3
Aib
=
N H
O
77
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
tecovirimatum tecovirimat
N-[1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro4,6-ethenocyclopropa[f]isoindol-2(1H)-yl]4-(trifluoromethyl)benzamide N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahydro4,6-éthénocyclopropa[f]isoindol-2(1H)-yl)4-(trifluorométhyl)benzamide N-(1,3-dioxo-3,3a,4,4a,5,5a,6,6a-octahidro4,6-etenociclopropa[f]isoindol-2(1H)-il)-4-(trifluorometil)benzamida C19H15F3N2O3 F3C H N O O N O
técovirimat
tecovirimat
teneligliptinum teneligliptin ténéligliptine teneligliptina
{(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin1-yl]pyrrolidin-2-yl}(1,3-thiazolidin-3-yl)methanone {(2S,4S)-4-[4-(3-méthyl-1-phényl-1H-pyrazol-5-yl)pipérazin1-yl]pyrrolidin-2-yl}(thiazolidin-3-yl)méthanone {(2S,4S)-4-[4-(1-fenil-3-metil-1H-pirazol-5-il)piperazin-1-il]pirrolidin2-il}(1,3-tiazolidin-3-il)metanona C22H30N6OS H N N N H3C N N O H H N S
tildipirosinum tildipirosin
(4R,5S,6S,7R,9R,11E,13E,15R,16R)-16-ethyl-4-hydroxy-5,9,13trimethyl-7-[2-(piperidin-1-yl)ethyl]-15-[(piperidin-1-yl)methyl]2,10-dioxooxacyclohexadeca-11,13-dien-6-yl β-D-glucopyranoside (+)-(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-{[3,6-didésoxy3-(diméthylamino)-β-D-glucopyranosyl]oxy}-16-éthyl-4-hydroxy5,9,13-triméthyl-7-[2-(pipéridin-1-yl)éthyl]-15-(pipéridin1-ylméthyl)oxacyclohexadéca-11,13-diène-2,10-dione β-D-glucopiranosido de (4R,5S,6S,7R,9R,11E,13E,15R,16R)-16-etil4-hidroxi-5,9,13-trimetil-7-[2-(piperidin-1-il)etil]-15-[(piperidin1-il)metil]-2,10-dioxooxaciclohexadeca-11,13-dien-6-ilo
tildipirosine
tildipirosina
78
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
C41H71N3O8 O
N CH3 H3C HO OH N H
H3C H
CH3 CH3 H O H O H3C N H H
O O CH3
H HO
tosedostatum tosedostat tosédostat tosedostat
cyclopentyl (2S)-2-{(2R)-2-[(S)-hydroxy(hydroxycarbamoyl)methyl]4-methylpentanamido}-2-phenylacetate (2S)-2-({(2R)-2-[(1S)-1-hydroxy-2-(hydroxyamino)-2-oxoéthyl]4-méthylpentanoyl}amino)-2-phénylacétate de cyclopentyle (2S)-2-{(2R)-2-[(S)-hidroxi(hidroxicarbamoil)metil]4-metilpentanamido}-2-fenilacetato de ciclopentilo C21H30N2O6 H3C O HO N H CH3 H H N H O O
H OH O
troplasminogenum alfa # troplasminogen alfa
thrombin-activable plasminogen: endo-[(558a(559)-558h(365))-human coagulation factor XI-(363370)-peptide]-des-(559-562)-[606(610)-lysine,623(627)-lysine]human plasminogen, glycoform α plasminogène activable par la thrombine : endo-[(558a(559)-558h(365))-facteur XI de coagulation humain(363-370)-peptide]-dès-(559-562)-[606(610)-lysine,623(627)lysine]plasminogène humain, glycoforme α plasminógeno activable por la trombina : endo-[(558a(559)-558h(365))-facteur XI de coagulación humano(363-370)-péptido]-des-(559-562)-[606(610)-lisina,623(627)-lisina] plasminógeno humano, glicoforma α
troplasminogène alfa
troplasminógeno alfa
79
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
C3875H5917N1107O1190S58 EPLDDYVNTQ EQQCVIMAEN NGITCQKWSS EKRYDYCDIL IPSKFPNKNL GPTYQCLKGT DENYCRNPDG LTPVVQDCYH GLTMNYCRNP LPDVETPSEE TNPRAGLEKN PQVEPKKCTT WVLTAAHCLK IALLKLSSPA LKEAQLPVIE CFEKDKYILQ GASLFSVTKK RKSSIIIRMR TSPHRPRFSP ECEEECMHCS KKNYCRNPDR GENYRGNVAV KRAPWCHTTN GDGQSYRGTS DADKGPWCFT DCMFGNGKGY YCRNPDGDVG KIKPRIVGGC KSPRPSSYKV VITDKVIPAC NKVCNRYEFL GVTSWGLGCA QLGAGSIEEC DVVLFEKKVY ATHPSEGLEE GENYDGKISK ELRPWCFTTD TVSGHTCQHW SQVRWEYCKI STTTTGKKCQ TDPSVRWEYC RGKRATTVTG GPWCYTTNPR VAHPHSWPWQ ILGAHQKVNL LPSPNYVVAD NGRVQSTELC RPNKPGVYVR AAKCEEDEEF LSECKTGNGK NYCRNPDNDP TMSGLECQAW PNKRWELCDI SAQTPHTHNR PSCDSSPVST SWSSMTPHRH NLKKCSGTEA TPCQDWAAQE KLYDYCDVPQ VSLRTRFGMH EPHVQEIEVS RTECFITGWG AGHLAGGTDS VSRFVTWIEG TCRAFQYHSK NYRGTMSKTK QGPWCYTTDP DSQSPHAHGY PRCTTPPPSS TPENFPCKNL EQLAPTAPPE QKTPENYPNA SVVAPPPVVL PHRHSIFTPE CAAPSFDCGK FCGGTLISPE RLFLEPTRKD ETQGTFGAGL CQGDSGGPLV VMRNN 50 100 150 200 250 300 350 400 450 500 550 600 650 700 750 795
Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 30-54 34-42 84-162 105-145 133-157 166-243 169-297 187-226 215-238 256-333 277-316 305-328 358-435 379-418 407-430 462-541 483-524 512-536 548-670 558-570 592-608 684-751 714-730 741-769
Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación Ser-249 Asn-289 Thr-346
ustekinumabum # ustekinumab
immunoglobulin G1, anti-[Homo sapiens interleukin 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF p40)], Homo sapiens monoclonal antibody, CNTO 1275; gamma1 heavy chain (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1-119) IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfide with kappa light chain (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (228-228":231231")-bisdisulfide dimer immunoglobulin G1, anti-[Homo sapiens interleukine 12B (IL12B, IL12 p40, natural killer cell stimulatory factor 2, NKSF2, cytotoxic lymphocyte maturation factor 2, CLMF2, CMLF2 p40)], Homo sapiens anticorps monoclonal, CNTO 1275; chaîne lourde gamma1 (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)-IGHJ4*01) [8.8.12] (1119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfure avec la chaîne légère kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (228228":231-231")-bisdisulfure inmunoglobulina G1, anti-[Homo sapiens interleukina 12B (IL12B, IL12 p40, factor 2 estimulante de las células natural killer NKSF2, factor 2 citotóxico de la maduraciòn de linfocitos, CLMF2, CMLF2 p40)], Homo sapiens anticuerpo monoclonal, CNTO 1275; cadena pesada gamma1 (1-449) [Homo sapiens VH (IGHV5-51-(IGHD)IGHJ4*01) [8.8.12] (1-119) -IGHG1*01, CH1 A1.4>S (120-449)], (222-214')-disulfuro con la cadena ligera kappa (1'-214') [Homo sapiens V-KAPPA (IGKV1D-16-IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (228-228":231-231")-bisdisulfuro C6482H10004N1712O2016S46
ustékinumab
ustekinumab
vadimezanum vadimezan vadimézan vadimezan
2-(6,7-dimethyl-9-oxo-9H-xanthen-4-yl)acetic acid acide (5,6-diméthyl-9-oxo-9H-xanthén-4-yl)acétique ácido 2-(6,7-dimetil-9-oxo-9H-xanten-4-ilo)ácetico
80
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
C17H14O4 O
H3C CH3
O CO2H
velneperitum velneperit velnépérit velneperit
(1r,4s)-4-(1,1-dimethylethanesulfonamido)N-[5-(trifluoromethyl)pyridin-2-yl]cyclohexanecarboxamide (1r,4s)-4-(1,1-diméthyléthanesulfonamido)N-[5-(trifluorométhyl)pyridin-2-yl]cyclohexanecarboxamide (1r,4s)-4-(1,1-dimetiletanosulfonamido)-N-[5-(trifluorometil)piridin2-il]ciclohexanocarboxamida C17H24F3N3O3S O H N H N H H N CF3
O O H3C H3C S CH3
81
Recommended INN: List 61
WHO Drug Information, Vol. 23, No. 1, 2009
AMENDMENTS TO PREVIOUS LISTS MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES MODIFICACIONES A LAS LISTAS ANTERIORES
Recommended International Nonproprietary Names (Rec. INN): List 35 Dénominations communes internationales recommandées (DCI Rec.): Liste 35 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 35 (WHO Drug Information, Vol. 9, No. 3, 1995) p. 7 delete cipamfylline replace cipamfyllinum
Recommended International Nonproprietary Names (Rec. INN): List 52 Dénominations communes internationales recommandées (DCI Rec.): Liste 52 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 52 (WHO Drug Information, Vol. 18, No. 3, 2004) p. 256 delete netupitant replace netupitantum
Recommended International Nonproprietary Names (Rec. INN): List 57 Dénominations communes internationales recommandées (DCI Rec.): Liste 57 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 57 (WHO Drug Information, Vol. 21, No. 1, 2007) p. 55 aclidinii bromidum aclidinium bromide
replace the chemical name by the following (3R)-3-{[hydroxydi(thiophen-2-yl)acetyl]oxy}-1-(3-phenoxypropyl)5 1λ -azabicyclo[2.2.2]octan-1-ylium bromide remplacer le nom chimique par le suivant bromure de (3R)-3-{[hydroxydi(thiophén-2-yl)acétyl]oxy}-1-(3-phénoxypropyl)5 1λ -azabicyclo[2.2.2]octan-1-ylium
bromure d’aclidinium
Recommended International Nonproprietary Names (Rec. INN): List 58 Dénominations communes internationales recommandées (DCI Rec.): Liste 58 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 58 (WHO Drug Information, Vol. 21, No. 3, 2007)
p. 264
aclidinii bromidum bromuro de aclidinio
sustitúyase el nombre químico por el siguiente bromuro de (3R)-1-(3-fenoxipropil)-3-{[hidroxidi(tiofen-2-yl)acetil]oxi}5 1λ -azabiciclo[2.2.2]octan-1-ilio
82
WHO Drug Information, Vol. 23, No. 1, 2009
Recommended INN: List 61
Recommended International Nonproprietary Names (Rec. INN): List 59 Dénominations communes internationales recommandées (DCI Rec.): Liste 59 Denominaciones Comunes Internacionales recomendadas (DCI Rec.): Lista 59 (WHO Drug Information, Vol. 22, No. 1, 2008) p. 63 delete rabeximod replace rabeximodum
Recommended International Non Proprietary Names (Rec. INN): List 60 Dénominations communes internationales recommandées (DCI Rec.): Liste 60 Denominaciones Comunes Internacionales Recomandadas (DCI Rec.): Lista 60 (WHO Drug Information, Vol. 22, No. 3, 2008) p. 232 delete eribaxaban replace eribaxabanum
# # #
Electronic structure available on Mednet: http://mednet.who.int/ Structure électronique disponible sur Mednet: http://mednet.who.int/ Estructura electrónica disponible en Mednet: http://mednet.who.int/
Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in proposed INN lists only. Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les listes des DCI proposées. El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en las listas de DCI propuestas.
83